Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.

被引：0
|
作者：
Cao, Guochun
Li, Xiaoyou
Liu, Delin
Zhu, Jinghua
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Dept Clin Oncol, Jiangsu Canc Hosp,Jiangsu Inst Canc Res, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China
[3] China Jinagsu Prov Inst Canc Res, Nanjing, Jiangsu, Peoples R China
[4] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16022
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [22] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
    Chen, Ming-Qiu
    Chen, Cheng
    Lu, Hai-Jie
    Xu, Ben-Hua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
  • [23] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [24] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
    Qiu, Hai-Bo
    THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
  • [25] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
    Qiu, Tianzhu
    Mingjie, Lu
    Dong, Yuwen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
  • [27] A phase II study of toripalimab combined with paclitaxel/carboplatin for the first-line treatment of advanced thymic carcinoma
    Hu, X.
    Zhu, H.
    Feng, Y.
    Lu, J.
    Liu, Y.
    Xing, P.
    Wang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1426 - S1426
  • [28] First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] First-line paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus
    Zhang, X.
    Shen, L.
    Li, J.
    Li, Y.
    Li, J.
    Jin, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Efficacy and safety of SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous cell carcinoma: A phase II study.
    Wang, Jinliang
    Zhang, Zhibo
    Yan, Xiang
    Ma, Junxun
    Zhang, Fan
    Song, Qi
    Zhang, Li
    Liu, Zhefeng
    Yang, Bo
    Wang, Lijie
    Tao, Haitao
    Zhang, Sujie
    Li, Xiaoyan
    Hu, Jie
    Li, Xiaoting
    Wang, Jiaqian
    Zhi, Xiaoyu
    Ge, Xiangwei
    Jiao, Shunchang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345